Adolor Drug Comes Up Short
126978
The company announces trial results that, once again, do not meet primary end points.
231086
New research has cast doubt on the effectiveness of one of the most commonly prescribed blood pressure-lowering drugs. A pooled data study found that while atenolol reduced blood pressure, it was no better
463333
AstraZeneca faced its third major setback in as many months yesterday after clinical trials dashed expectations that its lung cancer drug Iressa would develop into a blockbuster product that would dominate treatment around the world.
21611
One undervalued drug developer may be on the cusp of greatness.
147347
A more cautious Food and Drug Administration dealt Procter &amp; Gamble a setback in its bid to be first to market a drug to improve women&#39;s sex drive.
71580
Adolor Corp. said on Thursday its  experimental treatment for post-operative bowel obstruction did  not confer a significant benefit in a late-stage clinical trial  in Europe, sending its stock skidding.
578766
The company announces another slight delay with its lead drug.
87010
New data are due out on a promising cholesterol drug. But there are doubters.
228622
Consumer confidence in the drugs marketed to them using multi-million dollar-advertising campaigns was shaken again last week. People taking drugs with the active ingredient naproxen, such as Aleve, in a study
353068
MONDAY, Dec. 4 (HealthDay News) -- One of a new class of diabetes drugs delayed the progression of type 2 diabetes along with the need to add additional medications.
454431
The drug company's experimental treatment for Alzheimer's  failed to prove effective in a big clinical trial. The stock  closed Tuesday at $45.85 on the New York Stock Exchange before  falling 10 percent in after-hours trading following release of  the trial results.
448598
Drugs to raise so-called good cholesterol may still have a future despite the widely publicized failure last year of an experimental cholesterol treatment from Pfizer, researchers said.
298049
The pharmaceutical company reported a 5 percent increase in fourth-quarter earnings but said growth would slow this year as generic competition picked up.
402115
Two drugs provide good results in preliminary trials.
363785
Sales of the multiple sclerosis drug are picking up, but probably can't grow into the stock's valuation.
745053
The strategy of fighting AIDS in Africa with questionable generic drugs made in developing countries now lies in shambles as an Indian company withdrew its medicines last week because it can&#39;t guarantee they are potent enough.
493997
Baycol is a cholesterol-lowing drug taken off the market three years ago, but a new study suggests that may have been too little, too late.